Status
Conditions
Treatments
About
We propose to evaluate the contribution of a standardized process combining,
The primary objective of this study is to determine the rate of patients for whom this process has changed the treatment plan.
Full description
Recent clinical data confirm the possibility and clinical benefit of delivering a second irradiation with curative intent even if the commonly accepted maximum doses to OARs had been reached during the first irradiation.
However, there is no consensus on acceptable doses to AORs in a re-irradiation context. The difficulty of making decisions and validating dosimetry may limit access to treatment. Re-irradiations are therefore carried out according to local experience and equipment, resulting in territorial inequality.
MiM software is an innovative software dedicated to images registration and dose summation. It allows the EQD2 doses of the various irradiations to be cumulated.
Recruitment and inclusion step: For each included patient (signed consent form), the center provides an initial opinion concerning the indication for re-irradiation with curative intent (Opinion 1).
Indication and pre-dosimetric study step:
Study withdrawal if the indication for re-irradiation is not validated.
Cumulative doses validation step:
CT + RT structures+doses of the planned re-irradiation will be sent to CLB and EQD2 doses will be summed into MIM. If cumulative doses are accepted by consensus, multidisciplinary meeting will deliver the Opinion 4. Otherwise the center will have to do a new planimetry.
Patients for whom re-irradiation with curative intent has been declared possible will be followed for 2 years according to standard practices, approximately every 3 months and analyzed for tolerance and efficiency.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 18 years when signing the consent form
Re-irradiation with desired curative intent (≥ 50 Gy EQD2), with volume to be irradiated totally or partially included in a previous irradiation field:
Life expectancy > 6 months
Dated and signed informed consent
Affiliation to a social security scheme or equivalent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
100 participants in 1 patient group
Loading...
Central trial contact
Marie-Pierre SUNYACH, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal